GO
Loading...

CNBC Exclusive Video: Corporate America's Washington Agenda

CNBC.com
Wednesday, 21 Mar 2007 | 3:24 PM ET

Corporate America came to Washington Wednesday to meet with President Bush and Congressional leaders. The Business Roundtable is an association of leading American CEOs, heading companies with $4.5 trillion in annual revenues and more than 10 million employees.

Business Roundtable, Pt. 1
CNBC's Sue Herera talks with members of the Business Roundtable, including chairman Terry McGraw, McGraw Hill Companies CEO; Mike McCallister, Humana CEO and Bill Green, Accenture CEO. The Business Roundtable is meeting in Washington with Congressional leaders.

Before sitting down with the President to talk about U.S. competitiveness, trade expansion and education, three of the Roundtable's most influential leaders sat down with our Sue Herera for a "CNBC Exclusive" interview.

Business Roundtable, Pt. 2
CNBC's Sue Herera talks with members of the Business Roundtable, including chairman Terry McGraw, McGraw Hill Companies CEO; Mike McCallister, Humana CEO and Bill Green, Accenture CEO. The Business Roundtable is meeting in Washington with Congressional leaders.

An excerpt from that session appeared today on CNBC's Power Lunch. This is the complete discussion (in two parts) about Corporate America's Washington agenda, with McGraw Hill's Terry McGraw, Humana's Mike McCallister and Accenture's Bill Green.

Featured

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More

Don't Miss

U.S. Video

  • Mad Money's Jim Cramer discusses Micron Technology and how the company gained control over inventory issues. The bears expect the company's history to repeat itself, but Cramer says this time, it feels different.

  • In this excerpt from a live CNBC interview, Warren Buffett explains why it's extremely unusual for a company's directors to vote against executive compensation plans.

  • Mad Money host Jim Cramer says shareholder activism works for every shareholder, and offers his take on the Valeant/Bill Ackman bid to acquire Allergan. The market is better off for these efforts, he says.